WO2001053353A3 - Recombinant antibodies to human interkleukin-1 beta - Google Patents
Recombinant antibodies to human interkleukin-1 beta Download PDFInfo
- Publication number
- WO2001053353A3 WO2001053353A3 PCT/EP2001/000591 EP0100591W WO0153353A3 WO 2001053353 A3 WO2001053353 A3 WO 2001053353A3 EP 0100591 W EP0100591 W EP 0100591W WO 0153353 A3 WO0153353 A3 WO 0153353A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human
- interkleukin
- beta
- recombinant antibodies
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01905671A EP1248804B2 (en) | 2000-01-21 | 2001-01-19 | Recombinant antibodies to human interleukin-1 beta |
CN018039529A CN1395581B (en) | 2000-01-21 | 2001-01-19 | Recombinant antibodies to human IL-1 beta |
SI200130698T SI1248804T2 (en) | 2000-01-21 | 2001-01-19 | Recombinant antibodies to human interleukin-1 beta |
AU33697/01A AU772949B2 (en) | 2000-01-21 | 2001-01-19 | Antibodies to human IL-1beta |
NZ519936A NZ519936A (en) | 2000-01-21 | 2001-01-19 | Antibodies to human Interleukin-1 |
JP2001553825A JP3978338B2 (en) | 2000-01-21 | 2001-01-19 | Antibody against human IL-1β |
DE60124863T DE60124863T3 (en) | 2000-01-21 | 2001-01-19 | AGAINST HUMAN INTERLEUKIN-1-BETA RECOMBINANT ANTIBODIES |
PL356297A PL207642B1 (en) | 2000-01-21 | 2001-01-19 | Recombinant antibodies to human interkleukin-1 beta |
CA2396212A CA2396212C (en) | 2000-01-21 | 2001-01-19 | Recombinant antibodies to human interleukin-1 beta |
BR0107661-2A BR0107661A (en) | 2000-01-21 | 2001-01-19 | Antibodies to human il-1 / ß |
MXPA02007091A MXPA02007091A (en) | 2000-01-21 | 2001-01-19 | ANTIBODIES TO HUMAN IL 1bgr;. |
SK1035-2002A SK288054B6 (en) | 2000-01-21 | 2001-01-19 | Antibody to IL-1 beta, IL-1 beta binding molecule, its use and process for production, first DNA construct, expression vector and pharmaceutical composition |
HU0204156A HUP0204156A3 (en) | 2000-01-21 | 2001-01-19 | Recombinant antibodies to human interleukin-1 beta |
DK01905671.2T DK1248804T4 (en) | 2000-01-21 | 2001-01-19 | Recombinant antibodies to human interleukin-1 beta |
IL15055101A IL150551A0 (en) | 2000-01-21 | 2001-01-19 | Recombinant antibodies to human interleukin-1 beta |
IL150551A IL150551A (en) | 2000-01-21 | 2002-07-02 | Recombinant antibody to human interleukin-1 beta, pharmaceutical compositions comprising the same , dna construct encoding the same, a process for its production and uses thereof in the preparation of a medicament |
NO20023266A NO329816B1 (en) | 2000-01-21 | 2002-07-05 | Antibodies to human IL-10, their use, DNA constructs, expression vector, method of preparation and pharmaceutical composition |
ZA2002/05659A ZA200205659B (en) | 2000-01-21 | 2002-07-16 | Recombinant antibodies to human interleukin-1 beta |
HK03102022.5A HK1050013A1 (en) | 2000-01-21 | 2003-03-19 | ANTIBODIES TO HUMAN IL-1β |
US11/484,472 US7491392B2 (en) | 2000-01-21 | 2006-07-11 | Antibodies to human IL-1β |
US12/351,007 US20090232803A1 (en) | 2000-01-21 | 2009-01-09 | Antibodies to human il-1beta |
US13/044,918 US20110182894A1 (en) | 2000-01-21 | 2011-03-10 | Methods of treating diabetes using IL-1beta antibodies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0001448.0 | 2000-01-21 | ||
GBGB0001448.0A GB0001448D0 (en) | 2000-01-21 | 2000-01-21 | Organic compounds |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10181324 A-371-Of-International | 2001-01-19 | ||
US11/484,472 Continuation US7491392B2 (en) | 2000-01-21 | 2006-07-11 | Antibodies to human IL-1β |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001053353A2 WO2001053353A2 (en) | 2001-07-26 |
WO2001053353A3 true WO2001053353A3 (en) | 2002-04-04 |
Family
ID=9884137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/000591 WO2001053353A2 (en) | 2000-01-21 | 2001-01-19 | Recombinant antibodies to human interkleukin-1 beta |
Country Status (33)
Country | Link |
---|---|
US (4) | US20030124617A1 (en) |
EP (1) | EP1248804B2 (en) |
JP (2) | JP3978338B2 (en) |
KR (1) | KR100697126B1 (en) |
CN (1) | CN1395581B (en) |
AR (1) | AR027253A1 (en) |
AT (1) | ATE346868T1 (en) |
AU (1) | AU772949B2 (en) |
BR (1) | BR0107661A (en) |
CA (1) | CA2396212C (en) |
CO (1) | CO5261584A1 (en) |
CY (1) | CY1107989T1 (en) |
CZ (1) | CZ302738B6 (en) |
DE (1) | DE60124863T3 (en) |
DK (1) | DK1248804T4 (en) |
ES (1) | ES2274865T5 (en) |
GB (1) | GB0001448D0 (en) |
HK (1) | HK1050013A1 (en) |
HU (1) | HUP0204156A3 (en) |
IL (2) | IL150551A0 (en) |
MX (1) | MXPA02007091A (en) |
MY (1) | MY155269A (en) |
NO (1) | NO329816B1 (en) |
NZ (1) | NZ519936A (en) |
PE (1) | PE20011219A1 (en) |
PL (1) | PL207642B1 (en) |
PT (1) | PT1248804E (en) |
RU (1) | RU2264413C2 (en) |
SI (1) | SI1248804T2 (en) |
SK (1) | SK288054B6 (en) |
TR (1) | TR200201780T2 (en) |
WO (1) | WO2001053353A2 (en) |
ZA (1) | ZA200205659B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8465744B2 (en) | 2003-02-13 | 2013-06-18 | Ucb Pharma S.A. | Method of treating inflammation by administering human IL-1B antibodies |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0001448D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
CA2411374C (en) | 2000-06-29 | 2012-10-30 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
CN1652821A (en) * | 2002-01-28 | 2005-08-10 | 米德列斯公司 | Human monoclonal antibodies to prostate specific membrane antigen (PSMA) |
JP4711963B2 (en) * | 2003-09-15 | 2011-06-29 | オクラホマ メディカル リサーチ ファウンデーション | Methods using cytokine assays to diagnose, treat and evaluate inflammatory and autoimmune diseases |
PL1766093T3 (en) * | 2004-02-06 | 2011-11-30 | Univ Massachusetts | Antibodies against clostridium difficile toxins and uses thereof |
CA2590164A1 (en) | 2005-01-26 | 2006-08-03 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
JO3058B1 (en) * | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | Anti-IL-6 Antibodies,Compositions,Methods and uses |
SI2314623T1 (en) * | 2005-06-21 | 2012-11-30 | Xoma Technology Ltd | IL-1beta binding antibodies and fragments thereof |
EP3332807B1 (en) * | 2005-10-26 | 2023-02-22 | Novartis AG | Use of anti il-1beta antibodies |
ES2517420T3 (en) * | 2005-12-29 | 2014-11-03 | Janssen Biotech, Inc. | Human anti-IL-23 antibodies, compositions, procedures and uses |
US7943328B1 (en) | 2006-03-03 | 2011-05-17 | Prometheus Laboratories Inc. | Method and system for assisting in diagnosing irritable bowel syndrome |
WO2007120828A1 (en) * | 2006-04-14 | 2007-10-25 | Novartis Ag | Use of il-i antibodies for treating ophthalmic disorders |
US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
AU2007333635B2 (en) | 2006-12-20 | 2014-02-20 | Xoma (Us) Llc | Treatment of IL-1-beta related diseases |
EP2114443A4 (en) * | 2006-12-29 | 2011-08-10 | Abbott Lab | Dual-specific il-1a/ il-1b antibodies |
EP2417974A1 (en) | 2007-02-28 | 2012-02-15 | Schering Corporation | Combination therapy for treatment of immune disorders |
KR102606597B1 (en) * | 2007-05-29 | 2023-11-29 | 노파르티스 아게 | New indications for anti-il-1-beta therapy |
MX2010006823A (en) | 2007-12-20 | 2010-09-30 | Xoma Technology Ltd | Methods for the treatment of gout. |
EP2293816B1 (en) * | 2008-06-06 | 2012-11-07 | XOMA Technology Ltd. | Methods for the treatment of rheumatoid arthritis |
CA2735939A1 (en) | 2008-09-05 | 2010-03-11 | Xoma Technology Ltd. | Methods for improvement of beta cell function |
PL2493922T3 (en) | 2009-10-26 | 2017-07-31 | F.Hoffmann-La Roche Ag | Method for the production of a glycosylated immunoglobulin |
NZ603191A (en) | 2010-05-07 | 2015-02-27 | Xoma Technology Ltd | Methods for the treatment of il-1b related conditions |
DE102010033565B4 (en) * | 2010-07-27 | 2012-06-21 | Tetec Tissue Engineering Technologies Ag | Marker for the determination of chondrocytes |
JP6146913B2 (en) | 2010-08-02 | 2017-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Mice producing a binding protein containing a VL domain |
JP5866130B2 (en) * | 2010-09-10 | 2016-02-17 | アペクシジェン, インコーポレイテッド | Anti-IL-1β antibody and method of use thereof |
ES2748832T5 (en) | 2011-02-25 | 2023-06-08 | Regeneron Pharma | ADAM6 Mice |
EP3865581A1 (en) | 2011-08-05 | 2021-08-18 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
DE102011083595A1 (en) | 2011-09-28 | 2013-03-28 | Bayer Pharma AG | Inhibition of the effect of interleukin 1 beta for the treatment of endometriosis |
WO2013096516A1 (en) | 2011-12-19 | 2013-06-27 | Xoma Technology Ltd. | Methods for treating acne |
KR102081657B1 (en) | 2011-12-20 | 2020-02-26 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized light chain mice |
ES2798110T3 (en) | 2012-02-13 | 2020-12-09 | Agency Science Tech & Res | IL-beta neutralizing human monoclonal antibodies |
SG11201407789RA (en) | 2012-06-12 | 2014-12-30 | Regeneron Pharma | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
EP3119194B1 (en) | 2014-03-21 | 2021-04-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
CA2941514A1 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
CN110818793A (en) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | Antibodies against IL-1 β, pharmaceutical compositions thereof and uses thereof |
KR20210093973A (en) | 2018-11-20 | 2021-07-28 | 얀센 바이오테크 인코포레이티드 | A Safe and Effective Method of Treating Psoriasis with Anti-IL23 Specific Antibodies |
MX2021014302A (en) | 2019-05-23 | 2022-01-04 | Janssen Biotech Inc | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990006371A1 (en) * | 1988-12-08 | 1990-06-14 | Commissariat A L'energie Atomique | ANTI-INTERLEUKINE 1α AND 1β MONOCLONAL ANTIBODIES, METHOD FOR PRODUCING THE SAME AND APPLICATIONS OF SAID ANTIBODIES TO THE DETECTION OF INTERLEUKINES 1α AND 1β AND TO THERAPY |
WO1995001997A1 (en) * | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4772685A (en) | 1985-10-02 | 1988-09-20 | Merck & Co., Inc. | Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies |
US4935343A (en) * | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
JP3714683B2 (en) * | 1992-07-30 | 2005-11-09 | 生化学工業株式会社 | Anti-rheumatic agent |
US5429614A (en) | 1993-06-30 | 1995-07-04 | Baxter International Inc. | Drug delivery system |
US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
GB0001448D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
-
2000
- 2000-01-21 GB GBGB0001448.0A patent/GB0001448D0/en not_active Ceased
-
2001
- 2001-01-18 MY MYPI20010226A patent/MY155269A/en unknown
- 2001-01-18 CO CO01003434A patent/CO5261584A1/en active IP Right Grant
- 2001-01-19 CZ CZ20022531A patent/CZ302738B6/en not_active IP Right Cessation
- 2001-01-19 JP JP2001553825A patent/JP3978338B2/en not_active Expired - Fee Related
- 2001-01-19 CN CN018039529A patent/CN1395581B/en not_active Expired - Fee Related
- 2001-01-19 AT AT01905671T patent/ATE346868T1/en active
- 2001-01-19 HU HU0204156A patent/HUP0204156A3/en not_active Application Discontinuation
- 2001-01-19 AR ARP010100247A patent/AR027253A1/en active IP Right Grant
- 2001-01-19 SI SI200130698T patent/SI1248804T2/en unknown
- 2001-01-19 TR TR2002/01780T patent/TR200201780T2/en unknown
- 2001-01-19 US US10/181,324 patent/US20030124617A1/en not_active Abandoned
- 2001-01-19 WO PCT/EP2001/000591 patent/WO2001053353A2/en active IP Right Grant
- 2001-01-19 PL PL356297A patent/PL207642B1/en unknown
- 2001-01-19 SK SK1035-2002A patent/SK288054B6/en not_active IP Right Cessation
- 2001-01-19 NZ NZ519936A patent/NZ519936A/en not_active IP Right Cessation
- 2001-01-19 PE PE2001000065A patent/PE20011219A1/en not_active Application Discontinuation
- 2001-01-19 MX MXPA02007091A patent/MXPA02007091A/en active IP Right Grant
- 2001-01-19 PT PT01905671T patent/PT1248804E/en unknown
- 2001-01-19 ES ES01905671T patent/ES2274865T5/en not_active Expired - Lifetime
- 2001-01-19 AU AU33697/01A patent/AU772949B2/en not_active Ceased
- 2001-01-19 BR BR0107661-2A patent/BR0107661A/en not_active IP Right Cessation
- 2001-01-19 DE DE60124863T patent/DE60124863T3/en not_active Expired - Lifetime
- 2001-01-19 DK DK01905671.2T patent/DK1248804T4/en active
- 2001-01-19 EP EP01905671A patent/EP1248804B2/en not_active Expired - Lifetime
- 2001-01-19 IL IL15055101A patent/IL150551A0/en unknown
- 2001-01-19 KR KR1020027009374A patent/KR100697126B1/en not_active IP Right Cessation
- 2001-01-19 RU RU2002121649/13A patent/RU2264413C2/en not_active IP Right Cessation
- 2001-01-19 CA CA2396212A patent/CA2396212C/en not_active Expired - Fee Related
-
2002
- 2002-07-02 IL IL150551A patent/IL150551A/en not_active IP Right Cessation
- 2002-07-05 NO NO20023266A patent/NO329816B1/en not_active IP Right Cessation
- 2002-07-16 ZA ZA2002/05659A patent/ZA200205659B/en unknown
-
2003
- 2003-03-19 HK HK03102022.5A patent/HK1050013A1/en unknown
-
2006
- 2006-07-11 US US11/484,472 patent/US7491392B2/en not_active Expired - Fee Related
- 2006-12-29 CY CY20061101860T patent/CY1107989T1/en unknown
-
2007
- 2007-01-04 JP JP2007000148A patent/JP2007097598A/en active Pending
-
2009
- 2009-01-09 US US12/351,007 patent/US20090232803A1/en not_active Abandoned
-
2011
- 2011-03-10 US US13/044,918 patent/US20110182894A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990006371A1 (en) * | 1988-12-08 | 1990-06-14 | Commissariat A L'energie Atomique | ANTI-INTERLEUKINE 1α AND 1β MONOCLONAL ANTIBODIES, METHOD FOR PRODUCING THE SAME AND APPLICATIONS OF SAID ANTIBODIES TO THE DETECTION OF INTERLEUKINES 1α AND 1β AND TO THERAPY |
WO1995001997A1 (en) * | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
Non-Patent Citations (1)
Title |
---|
MATSUDA F ET AL: "The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus.", JOURNAL OF EXPERIMENTAL MEDICINE, (1998 DEC 7) 188 (11) 2151-62., XP001008659 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8465744B2 (en) | 2003-02-13 | 2013-06-18 | Ucb Pharma S.A. | Method of treating inflammation by administering human IL-1B antibodies |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001053353A3 (en) | Recombinant antibodies to human interkleukin-1 beta | |
WO2002016436A3 (en) | ANTIBODIES TO HUMAN IL-1$g(b) | |
WO2002090566A3 (en) | Recombinant tumor specific antibody and use thereof | |
WO2003030833A3 (en) | Angiopoietin-2 specific binding agents | |
WO2005052000A3 (en) | Anti-il-20 antibodies and binding partners and methods of using in inflammation | |
WO2004092215A3 (en) | Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2 | |
IL195085A0 (en) | Antibody molecules having specifity for human tnf ?? compounds and composition comprising them, dna sequence encoding heavy and light chain of said antibody and process for the production of said antibody | |
TNSN07034A1 (en) | Il - 17 antagonistic antibodies | |
EP2221317A3 (en) | PEGylated single domain antibodies (dAb) | |
WO2004067568A3 (en) | Human il-1 beta antagonists | |
WO2006068975A3 (en) | Binding proteins specific for human matriptase | |
WO2007117749A3 (en) | Il-17 antagonistic antibodies fpr treating cancer | |
WO2007047829A3 (en) | Novel heterodimeric proteins and uses thereof | |
WO2002044217A3 (en) | Humanised antibodies and uses thereof | |
WO2001068708A3 (en) | Human and humanized fap-alpha-specific antibodies | |
WO2001055178A3 (en) | Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer | |
EP2017343A3 (en) | Protein A based binding domains with desirable activities | |
ATE550345T1 (en) | SFRP, SFRP-INTERACTING PEPTIDE MOTIVES AND METHODS OF USE | |
GB0119015D0 (en) | A fusion protein | |
WO2008141511A8 (en) | A HUMAN ANTI-TNFα MONOCLONAL ANTIBODY AND THE USE THEREOF | |
WO2002081514A3 (en) | A novel f-box protein | |
WO2005000896A3 (en) | Polypeptides that bind an anti-tissue factor antibody and uses thereof | |
WO2003099863A3 (en) | Resistin binding proteins, their preparation and use | |
WO2003038440A3 (en) | Chemokine binding molecules | |
WO2001075006A3 (en) | A novel poypeptide, light chain of protein lattice 37 and the polynucleotide encoding the polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1200200755 Country of ref document: VN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001905671 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 33697/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 150551 Country of ref document: IL Ref document number: 519936 Country of ref document: NZ Ref document number: 2396212 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/01780 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10352002 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/05659 Country of ref document: ZA Ref document number: 200205659 Country of ref document: ZA Ref document number: 10181324 Country of ref document: US Ref document number: IN/PCT/2002/1094/CHE Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2001 553825 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/007091 Country of ref document: MX Ref document number: PV2002-2531 Country of ref document: CZ Ref document number: 018039529 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027009374 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002121649 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027009374 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001905671 Country of ref document: EP Ref document number: PV2002-2531 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 519936 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 519936 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 33697/01 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001905671 Country of ref document: EP |